Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease

Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases

(2016) Bella Ungar et al.   Clinical Gastroenterology and Hepatology

Does Smoking Reduce Infliximab’s Effectiveness against Crohn’s Disease?

(2016) Neeraj Narula et al.   CANADIAN JOURNAL OF GASTROENTEROLOGY

Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management

(2015) N. S. Ding et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis

(2015) M. J. Rosen et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation

(2015) Kaija-Leena Kolho et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

(2015) L Peyrin-Biroulet et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study

(2015) Ryota Iwasa et al.   BMC GASTROENTEROLOGY

Optimizing biologic treatment in IBD: objective measures, but when, how and how often?

(2015) Shomron Ben-Horin et al.   BMC GASTROENTEROLOGY

A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis

(2015) Maria Theresa Arias et al.   Clinical Gastroenterology and Hepatology

Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti–Tumor Necrosis Factor Therapy for Crohn’s Disease: A Meta-analysis of Placebo-controlled Trials

(2015) Jennifer L. Jones et al.   Clinical Gastroenterology and Hepatology

Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab

(2015) Henit Yanai et al.   Clinical Gastroenterology and Hepatology

An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis

(2015) David J. Gibson et al.   Clinical Gastroenterology and Hepatology

Azathioprine discontinuation earlier than 6 months in Crohn’s disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation

(2015) Nikos Viazis et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

(2015) Niels Vande Casteele et al.   GASTROENTEROLOGY

Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis

(2015) Johannan F. Brandse et al.   GASTROENTEROLOGY

Immunogenicity to infliximab is associated with HLA-DRB1

(2015) Thomas Billiet et al.   GUT

Factors Associated with Durable Response to Infliximab in Crohnʼs Disease 5 Years and Beyond

(2015) Pascal Juillerat et al.   INFLAMMATORY BOWEL DISEASES

Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients

(2015) Florenzo Iannone et al.   JOINT BONE SPINE

P471. Infliximab trough levels are lower in patients with acute severe, compared to moderate-severe ulcerative colitis patients

(2015)   Journal of Crohns & Colitis

Ashkenazi Jewish Origin Protects Against Formation of Antibodies to Infliximab and Therapy Failure

(2015) Bella Ungar et al.   MEDICINE

Genetic polymorphism inATG16L1gene influences the response to adalimumab in Crohn's disease patients

(2015) Silvo Koder et al.   PHARMACOGENOMICS

565 Novel Infliximab (IFX) and Antibody-to-Infliximab (ATI) Assays are Predictive of Disease Activity in Patients With Crohn's Disease (CD)

(2015) Brian G. Feagan et al.   GASTROENTEROLOGY

Tu1158 Evaluating Adalimumab Drug and Antibody Levels As Predictors of Clinical and Laboratory Response in Crohn's Disease Patients

(2015) Yoav Mazor et al.   GASTROENTEROLOGY

Adalimumab in Crohn's disease patients: pharmacokinetics in the first 6 months of treatment

(2014) M. R. K. L. Lie et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year

(2014) Luisa Guidi et al.   DIGESTIVE AND LIVER DISEASE

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial

(2014) Freddy Cornillie et al.   GUT

Clinical Utility of Fecal Biomarkers for the Diagnosis and Management of Inflammatory Bowel Disease

(2014) Uri Kopylov et al.   INFLAMMATORY BOWEL DISEASES

Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysis

(2014) Uri Kopylov et al.   Journal of Crohns & Colitis

Smoking and Early Infliximab Response in Crohn's Disease: a Meta-analysis

(2014) S. Inamdar et al.   Journal of Crohns & Colitis

Adalimumab for Crohn's disease: Long-term sustained benefit in a population-based cohort of 438 patients

(2014) Charlotte P. Peters et al.   Journal of Crohns & Colitis

Serological markers associated with disease behavior and response to anti-tumor necrosis factor therapy in ulcerative colitis

(2014) David Kevans et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease

(2014) Raja Atreya et al.   NATURE MEDICINE

The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease

(2014) Kaija-Leena Kolho et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn’s disease

(2014) Diamantis Thomas   WORLD JOURNAL OF GASTROENTEROLOGY

Surgical treatment of ulcerative colitis: Ileorectalvsileal pouch-anal anastomosis

(2014) Daniele Scoglio   WORLD JOURNAL OF GASTROENTEROLOGY

Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors

(2013) A. C. Moss et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

(2013) Niels Vande Casteele et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Optimizing anti-TNF treatments in inflammatory bowel disease

(2013) Shomron Ben-Horin et al.   AUTOIMMUNITY REVIEWS

Phenotypic Features of Crohn's Disease Associated With Failure of Medical Treatment

(2013) Gordon W. Moran et al.   Clinical Gastroenterology and Hepatology

Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease

(2013) Jean–Frédéric Colombel et al.   Clinical Gastroenterology and Hepatology

Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases

(2013) Xavier Roblin et al.   Clinical Gastroenterology and Hepatology

Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn’s disease?

(2013) Mahesh Bhalme et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease

(2013) Brian G. Feagan et al.   GASTROENTEROLOGY

Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease

(2013) Ana Gutiérrez et al.   GUT

The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab

(2013) Bella Ungar et al.   GUT

Increased Body Mass Index Is Associated with Earlier Time to Loss of Response to Infliximab in Patients with Inflammatory Bowel Disease

(2013) Jason W. Harper et al.   INFLAMMATORY BOWEL DISEASES

Consecutive Fecal Calprotectin Measurements to Predict Relapse in Patients with Ulcerative Colitis Receiving Infliximab Maintenance Therapy

(2013) Martine De Vos et al.   INFLAMMATORY BOWEL DISEASES

Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease

(2013) Stephane Paul et al.   INFLAMMATORY BOWEL DISEASES

High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment

(2013) Fernando Magro et al.   Journal of Crohns & Colitis

C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I

(2012) W. Reinisch et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays

(2012) N. Vande Casteele et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis

(2012) Maša Umiċeviċ Mirkov et al.   ANNALS OF THE RHEUMATIC DISEASES

Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease

(2012) Shomron Ben–Horin et al.   Clinical Gastroenterology and Hepatology

Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents

(2012) Pauliina Molander et al.   INFLAMMATORY BOWEL DISEASES

P360 Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease: A single cohort study

(2012) M. Bortlik et al.   Journal of Crohns & Colitis

Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum

(2012) Shui-Long Wang et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Assessing Response and Loss of Response to Biological Therapies in IBD

(2011) Henit Yanai et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease

(2011) Matthias Jürgens et al.   Clinical Gastroenterology and Hepatology

Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials

(2011) Adedigbo A. Fasanmade et al.   CLINICAL THERAPEUTICS

Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis

(2011) Jean Frédéric Colombel et al.   GASTROENTEROLOGY

Epidemiology and Natural History of Inflammatory Bowel Diseases

(2011) Jacques Cosnes et al.   GASTROENTEROLOGY

Combination of genetic and quantitative serological immune markers are associated with complicated Crohnʼs disease behavior

(2011) Gary R. Lichtenstein et al.   INFLAMMATORY BOWEL DISEASES

Predictors of adalimumab dose escalation in patients with crohnʼs disease at a tertiary referral center

(2011) Russell D. Cohen et al.   INFLAMMATORY BOWEL DISEASES

Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies

(2011) Uri Kopylov et al.   INFLAMMATORY BOWEL DISEASES

Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis

(2011) A.A. Fasanmade et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience

(2011) Michael B. Sprakes et al.   Journal of Crohns & Colitis

A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy and Hospitalization

(2010) Abderrahim Oussalah et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Response?

(2010) Geert R D'Haens et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

(2010) Waqqas Afif et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Disease Activity, ANCA and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis

(2010) Matthias Jürgens et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful

(2010) S. Ben-Horin et al.   GUT

Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy

(2010) H. Sokol et al.   GUT

Monitoring functional serum antitumor necrosis factor antibody level in Crohnʼs disease patients who maintained and those who lost response to anti-TNF

(2010) Akihiro Yamada et al.   INFLAMMATORY BOWEL DISEASES

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fecal Calprotectin Predicts the Clinical Course of Acute Severe Ulcerative Colitis

(2009) G T Ho et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

(2009) Javier P Gisbert et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

(2009) Adedigbo A. Fasanmade et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

(2009) Konstantinos Karmiris et al.   GASTROENTEROLOGY

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

(2009) C H Seow et al.   GUT

Genome wide association (GWA) predictors of anti-TNFα therapeutic responsiveness in pediatric inflammatory bowel disease

(2009) Marla C. Dubinsky et al.   INFLAMMATORY BOWEL DISEASES

Review: Predicting response to anti-TNF agents for the treatment of Crohn's disease

(2009) Corey A. Siegel et al.   Therapeutic Advances in Gastroenterology

Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial

(2008) Gert Van Assche et al.   GASTROENTEROLOGY

Long-term outcome after infliximab for refractory ulcerative colitis

(2008) Marc Ferrante et al.   Journal of Crohns & Colitis

Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease

(2007) Mark A. Ainsworth et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY